By Fineline Cube Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced plans to enter into an exclusive licensing agreement with Shenyang 3SBio Co., Ltd. The deal grants 3SBio extensive rights, including development, regulatory, manufacturing, use, sales, export, and import, for its antitumor programs 602, 609, 705, and ophthalmology program 601A, as well as HanBio Therapeutics’ 707 in China mainland and the United States.
Intellectual Property Rights Transfer and Deal Expansion
Additionally, the two companies have signed an intellectual property (IP) rights transfer agreement, which transfers all rights to the CD20 monoclonal antibody (mAb) 304R to Shenyang 3SBio for a consideration of RMB 99.3 million (USD 14.34 million). Both companies are under the control of LOU JING, with Shenyang 3SBio holding a 6.42% stake in Sunshine Guojian.
Details of the Antitumor and Ophthalmology Programs
- Recombinant anti EGFR human-mouse chimeric mAb 602: An independently developed antibody-drug for the treatment of metastatic colorectal cancer. Phase II clinical studies have been completed, and discussions with the CDE for Phase III clinical protocol are underway.
- Recombinant anti-PD-1 mAb 609: An antibody drug for the treatment of solid tumors, currently in Phase II clinical trials for advanced undifferentiated pleomorphic sarcoma (UPS).
- Bispecific antibody (BsAb) 705: Targets HER2 and PD-1, filed in China and the United States, and currently in Phase I clinical trials.
- Recombinant anti VEGF mAb 601A: A recombinant IgG1 developed for the treatment of retinal branch vein occlusion (BRVO), with the Phase III clinical trial protocol approved by the National Medical Products Administration.
- 707: A PD-1 and VEGF BsAb developed using the company’s dual antibody platform, currently in the Phase I stage.
- Recombinant human-mouse chimeric anti-CD20 mAb 304R: A chimeric mAb that specifically binds to CD20 antigen on human B lymphocytes, mediating B cell lysis. The drug has completed Phase III clinical trials and is currently undergoing protocol modifications based on feedback from the Center for Drug Evaluation (CDE).-Fineline Info & Tech